HOME >> BIOLOGY >> NEWS
Vaccine technique shows potential against common form of lung cancer

BOSTON In a demonstration of vaccine therapys potential for treating lung cancer, Dana-Farber Cancer Institute scientists and their associates report that a prototype vaccine boosted the natural immune response to tumors in a small group of patients with advanced non-small cell lung cancer (NSCLC). Moreover, the vaccine was found to be non-toxic and well-tolerated.

Published in the Feb. 15 issue of the Journal of Clinical Oncology, findings from the Phase I clinical trial will provide an impetus for further efforts to develop a vaccine against NSCLC, a difficult-to-treat condition that accounts for roughly 80 percent of all lung cancer cases. (Phase I trials are designed primarily to assess the safety of an experimental treatment.)

"This work represents a new approach to a vaccine for lung cancer patients, says senior author Glenn Dranoff, MD, of Dana-Farber. "Were still at an early stage, but the results of this study are encouraging. They offer a 'proof of principle' that this technique can strengthen the normal immune response to NSCLC tumors and will help form the basis for testing the vaccine in patients with earlier stage lung cancer."

The technique was originally developed for patients with advanced melanoma, a form of cancer that begins in the skin but can be deadly if allowed to spread to other parts of the body.

The researchers created the melanoma vaccine by removing a portion of a patients tumor and using specially equipped viruses to insert a gene known as GM-CSF into the tumor cells. After being radiated and injected into the patient, the manipulated tumor cells began producing the granulocyte-macrophage colony-stimulating factor (GM-CSF) protein, which acted as a magnet for an immune system attack on tumor cells. As the researchers had hoped, the vaccine elicited a potent, long-lasting immune response targeted at the melanoma tumor cells and produced only minor side effects.

In the lung cancer study,
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
13-Feb-2003


Page: 1 2

Related biology news :

1. Hope Clinic of Emory Vaccine Center receives CDC contract
2. Vaccines against foodborne disease on horizon
3. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
4. Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV
5. Emory Vaccine Research Center study identifies specific gene required for long-term immunity
6. Vaccine prevents stroke in rats
7. Vaccine puts blood-sucking ticks off their food
8. Vaccine protects against fatal West Nile complication
9. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
10. Vaccine controls AIDS in monkeys, researchers report in Science
11. Vaccine put into tomatoes shows promise fighting virus in lab tests

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
Cached News: